Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

ACB vs TLRY

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
ACB
Aurora Cannabis Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • CA
Market Cap$195M
5Y Perf.-97.6%
TLRY
Tilray Brands, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • CA
Market Cap$660M
5Y Perf.-42.5%

ACB vs TLRY — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
ACB logoACB
TLRY logoTLRY
IndustryDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & Generic
Market Cap$195M$660M
Revenue (TTM)$361M$1.17B
Net Income (TTM)$41M$-2.95B
Gross Margin62.7%28.0%
Operating Margin13.3%-266.0%
Forward P/E164.2x
Total Debt$104M$451M
Cash & Equiv.$184M$304M

ACB vs TLRYLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

ACB
TLRY
StockMay 20May 26Return
Aurora Cannabis Inc. (ACB)1002.4-97.6%
Tilray Brands, Inc. (TLRY)10057.5-42.5%

Price return only. Dividends and distributions are not included.

Quick Verdict: ACB vs TLRY

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ACB leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Tilray Brands, Inc. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
ACB
Aurora Cannabis Inc.
The Income Pick

ACB carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • beta 1.81
  • Rev growth 27.0%, EPS growth 102.2%, 3Y rev CAGR 15.8%
  • Lower volatility, beta 1.81, Low D/E 17.2%, current ratio 4.31x
Best for: income & stability and growth exposure
TLRY
Tilray Brands, Inc.
The Long-Run Compounder

TLRY is the clearest fit if your priority is long-term compounding.

  • -74.7% 10Y total return vs ACB's -92.0%
  • +12.1% vs ACB's -25.3%
Best for: long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthACB logoACB27.0% revenue growth vs TLRY's 4.8%
Quality / MarginsACB logoACB11.2% margin vs TLRY's -252.6%
Stability / SafetyACB logoACBBeta 1.81 vs TLRY's 2.03, lower leverage
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)TLRY logoTLRY+12.1% vs ACB's -25.3%
Efficiency (ROA)ACB logoACB5.2% ROA vs TLRY's -100.6%, ROIC 0.7% vs -66.2%

ACB vs TLRY — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

ACBAurora Cannabis Inc.

Segment breakdown not available.

TLRYTilray Brands, Inc.
FY 2025
Cannabis Segment
36.1%$331M
Distribution Revenue
29.6%$271M
Beverage Alcohol Business
27.7%$253M
Wellness Business
6.6%$60M

ACB vs TLRY — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLACBLAGGINGTLRY

Income & Cash Flow (Last 12 Months)

ACB leads this category, winning 4 of 6 comparable metrics.

TLRY is the larger business by revenue, generating $1.2B annually — 3.2x ACB's $361M. ACB is the more profitable business, keeping 11.2% of every revenue dollar as net income compared to TLRY's -2.5%. On growth, ACB holds the edge at +6.8% YoY revenue growth, suggesting stronger near-term business momentum.

MetricACB logoACBAurora Cannabis I…TLRY logoTLRYTilray Brands, In…
RevenueTrailing 12 months$361M$1.2B
EBITDAEarnings before interest/tax$71M-$3.0B
Net IncomeAfter-tax profit$41M-$2.9B
Free Cash FlowCash after capex-$31M-$94M
Gross MarginGross profit ÷ Revenue+62.7%+28.0%
Operating MarginEBIT ÷ Revenue+13.3%-2.7%
Net MarginNet income ÷ Revenue+11.2%-2.5%
FCF MarginFCF ÷ Revenue-8.7%-8.1%
Rev. Growth (YoY)Latest quarter vs prior year+6.8%+3.0%
EPS Growth (YoY)Latest quarter vs prior year-94.5%+70.7%
ACB leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

TLRY leads this category, winning 3 of 3 comparable metrics.
MetricACB logoACBAurora Cannabis I…TLRY logoTLRYTilray Brands, In…
Market CapShares × price$195M$660M
Enterprise ValueMkt cap + debt − cash$136M$806M
Trailing P/EPrice ÷ TTM EPS164.21x-0.17x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple6.73x
Price / SalesMarket cap ÷ Revenue0.77x0.59x
Price / BookPrice ÷ Book value/share0.43x0.25x
Price / FCFMarket cap ÷ FCF
TLRY leads this category, winning 3 of 3 comparable metrics.

Profitability & Efficiency

ACB leads this category, winning 9 of 9 comparable metrics.

ACB delivers a 7.2% return on equity — every $100 of shareholder capital generates $7 in annual profit, vs $-137 for TLRY. ACB carries lower financial leverage with a 0.17x debt-to-equity ratio, signaling a more conservative balance sheet compared to TLRY's 0.22x. On the Piotroski fundamental quality scale (0–9), ACB scores 7/9 vs TLRY's 4/9, reflecting strong financial health.

MetricACB logoACBAurora Cannabis I…TLRY logoTLRYTilray Brands, In…
ROE (TTM)Return on equity+7.2%-136.5%
ROA (TTM)Return on assets+5.2%-100.6%
ROICReturn on invested capital+0.7%-66.2%
ROCEReturn on capital employed+0.7%-78.1%
Piotroski ScoreFundamental quality 0–974
Debt / EquityFinancial leverage0.17x0.22x
Net DebtTotal debt minus cash-$80M$147M
Cash & Equiv.Liquid assets$184M$304M
Total DebtShort + long-term debt$104M$451M
Interest CoverageEBIT ÷ Interest expense6.27x-89.43x
ACB leads this category, winning 9 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

TLRY leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in TLRY five years ago would be worth $3,498 today (with dividends reinvested), compared to $385 for ACB. Over the past 12 months, TLRY leads with a +1209.3% total return vs ACB's -25.3%. The 3-year compound annual growth rate (CAGR) favors TLRY at 26.7% vs ACB's -19.2% — a key indicator of consistent wealth creation.

MetricACB logoACBAurora Cannabis I…TLRY logoTLRYTilray Brands, In…
YTD ReturnYear-to-date-21.0%-41.8%
1-Year ReturnPast 12 months-25.3%+1209.3%
3-Year ReturnCumulative with dividends-47.2%+103.6%
5-Year ReturnCumulative with dividends-96.1%-65.0%
10-Year ReturnCumulative with dividends-92.0%-74.7%
CAGR (3Y)Annualised 3-year return-19.2%+26.7%
TLRY leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

ACB leads this category, winning 2 of 2 comparable metrics.

ACB is the less volatile stock with a 1.81 beta — it tends to amplify market swings less than TLRY's 2.03 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ACB currently trades 51.4% from its 52-week high vs TLRY's 36.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricACB logoACBAurora Cannabis I…TLRY logoTLRYTilray Brands, In…
Beta (5Y)Sensitivity to S&P 5001.81x2.03x
52-Week HighHighest price in past year$6.67$15.70
52-Week LowLowest price in past year$3.07$0.35
% of 52W HighCurrent price vs 52-week peak+51.4%+36.1%
RSI (14)Momentum oscillator 0–10052.237.9
Avg Volume (50D)Average daily shares traded979K4.7M
ACB leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Wall Street rates ACB as "Hold" and TLRY as "Hold". Consensus price targets imply 76.7% upside for TLRY (target: $10) vs 72.6% for ACB (target: $6).

MetricACB logoACBAurora Cannabis I…TLRY logoTLRYTilray Brands, In…
Analyst RatingConsensus buy/hold/sellHoldHold
Price TargetConsensus 12-month target$5.92$10.00
# AnalystsCovering analysts1420
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

ACB leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). TLRY leads in 2 (Valuation Metrics, Total Returns).

Best OverallAurora Cannabis Inc. (ACB)Leads 3 of 6 categories
Loading custom metrics...

ACB vs TLRY: Frequently Asked Questions

8 questions · data-driven answers · updated daily

01

Is ACB or TLRY a better buy right now?

For growth investors, Aurora Cannabis Inc.

(ACB) is the stronger pick with 27. 0% revenue growth year-over-year, versus 4. 8% for Tilray Brands, Inc. (TLRY). Aurora Cannabis Inc. (ACB) offers the better valuation at 164. 2x trailing P/E, making it the more compelling value choice. Analysts rate Aurora Cannabis Inc. (ACB) a "Hold" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — ACB or TLRY?

Over the past 5 years, Tilray Brands, Inc.

(TLRY) delivered a total return of -65. 0%, compared to -96. 1% for Aurora Cannabis Inc. (ACB). Over 10 years, the gap is even starker: TLRY returned -74. 7% versus ACB's -92. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — ACB or TLRY?

By beta (market sensitivity over 5 years), Aurora Cannabis Inc.

(ACB) is the lower-risk stock at 1. 81β versus Tilray Brands, Inc. 's 2. 03β — meaning TLRY is approximately 12% more volatile than ACB relative to the S&P 500. On balance sheet safety, Aurora Cannabis Inc. (ACB) carries a lower debt/equity ratio of 17% versus 22% for Tilray Brands, Inc. — giving it more financial flexibility in a downturn.

04

Which is growing faster — ACB or TLRY?

By revenue growth (latest reported year), Aurora Cannabis Inc.

(ACB) is pulling ahead at 27. 0% versus 4. 8% for Tilray Brands, Inc. (TLRY). On earnings-per-share growth, the picture is similar: Aurora Cannabis Inc. grew EPS 102. 2% year-over-year, compared to -651. 7% for Tilray Brands, Inc.. Over a 3-year CAGR, ACB leads at 15. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — ACB or TLRY?

Aurora Cannabis Inc.

(ACB) is the more profitable company, earning 0. 5% net margin versus -266. 3% for Tilray Brands, Inc. — meaning it keeps 0. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACB leads at 1. 4% versus -277. 9% for TLRY. At the gross margin level — before operating expenses — ACB leads at 54. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — ACB or TLRY?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

07

Is ACB or TLRY better for a retirement portfolio?

For long-horizon retirement investors, Aurora Cannabis Inc.

(ACB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Tilray Brands, Inc. (TLRY) carries a higher beta of 2. 03 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ACB: -92. 0%, TLRY: -74. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between ACB and TLRY?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ACB is a small-cap high-growth stock; TLRY is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

ACB

Steady Growth Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 6%
Run This Screen
Stocks Like

TLRY

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 16%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform ACB and TLRY on the metrics below

Revenue Growth>
%
(ACB: 6.8% · TLRY: 3.0%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.